DE69219782T2 - Verwendung eines thymosins bei der behandlung von hepatitis c - Google Patents

Verwendung eines thymosins bei der behandlung von hepatitis c

Info

Publication number
DE69219782T2
DE69219782T2 DE69219782T DE69219782T DE69219782T2 DE 69219782 T2 DE69219782 T2 DE 69219782T2 DE 69219782 T DE69219782 T DE 69219782T DE 69219782 T DE69219782 T DE 69219782T DE 69219782 T2 DE69219782 T2 DE 69219782T2
Authority
DE
Germany
Prior art keywords
thymosin
treating hepatitis
immune system
potentiating
pref
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69219782T
Other languages
English (en)
Other versions
DE69219782D1 (de
Inventor
Milton Mutchnick
Paul Chretian
Kenneth E Sherman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
THE UNITED STATES OF AMERICA AS REPRESENTED BY THE
Wayne State University
Sciclone Pharmaceuticals LLC
Original Assignee
Wayne State University
Alpha 1 Biomedicals Inc
US Department of Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wayne State University, Alpha 1 Biomedicals Inc, US Department of Army filed Critical Wayne State University
Application granted granted Critical
Publication of DE69219782D1 publication Critical patent/DE69219782D1/de
Publication of DE69219782T2 publication Critical patent/DE69219782T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
DE69219782T 1991-09-13 1992-09-08 Verwendung eines thymosins bei der behandlung von hepatitis c Expired - Lifetime DE69219782T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75954491A 1991-09-13 1991-09-13
PCT/US1992/007556 WO1993005806A1 (en) 1991-09-13 1992-09-08 Composition and method of treating hepatitis c

Publications (2)

Publication Number Publication Date
DE69219782D1 DE69219782D1 (de) 1997-06-19
DE69219782T2 true DE69219782T2 (de) 1997-10-09

Family

ID=25056052

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69219782T Expired - Lifetime DE69219782T2 (de) 1991-09-13 1992-09-08 Verwendung eines thymosins bei der behandlung von hepatitis c

Country Status (23)

Country Link
US (3) US6001799A (de)
EP (1) EP0603305B1 (de)
JP (1) JP3228512B2 (de)
KR (1) KR100254082B1 (de)
AT (1) ATE152914T1 (de)
AU (1) AU667327B2 (de)
CA (1) CA2119006C (de)
CZ (1) CZ286827B6 (de)
DE (1) DE69219782T2 (de)
DK (1) DK0603305T3 (de)
ES (1) ES2103966T3 (de)
FI (1) FI107879B (de)
GR (1) GR3024025T3 (de)
HK (1) HK1021687A1 (de)
HU (1) HU221006B1 (de)
MX (1) MX9205240A (de)
NO (1) NO941310L (de)
RO (1) RO111991B1 (de)
RU (1) RU2104010C1 (de)
SG (1) SG64897A1 (de)
TW (1) TW224053B (de)
WO (1) WO1993005806A1 (de)
ZA (1) ZA926964B (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW224053B (de) * 1991-09-13 1994-05-21 Paul B Chretien
SG64892A1 (en) * 1992-02-06 1999-05-25 Sciclone Pharmaceuticals Method for treating hepatitis b carriers with minimal disease
WO1994001125A1 (en) * 1992-07-13 1994-01-20 Sherman Kenneth E Composition and method of treating hepatitis b
AU751199B2 (en) * 1992-07-13 2002-08-08 Government Of The United States Of America As Represented By The Secretary Of The Army Composition and method of treating hepatitis B
CN1072961C (zh) * 1993-03-05 2001-10-17 施塞克龙药品公司 治疗对干扰素治疗无反应者的丙型肝炎的方法
US6200952B1 (en) 1993-06-02 2001-03-13 Sciclone Pharmaceuticals, Inc. Combination therapy method for treating chronic hepatitis B
TW249754B (de) * 1993-10-26 1995-06-21 Alpha I Biomedicals Inc
MXPA94003453A (es) * 1993-11-05 2004-08-16 Alpha 1 Biomedicals Inc Metodo y composicion para el tratamiento de pacientes con hepatitis b que tienen descompensacion hepatica.
JP3837769B2 (ja) * 1995-06-12 2006-10-25 大塚製薬株式会社 抗ウイルス剤
GEP20012489B (en) * 1996-02-28 2001-07-25 Ifi Inst Farmacoterapico Italiano S P A Use of Natural Human α-Interferon
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
CN1315862C (zh) 2000-05-26 2007-05-16 艾登尼科斯（开曼）有限公司 处理黄病毒和瘟病毒的方法和组合物
US7208167B2 (en) * 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
MXPA03001145A (es) * 2000-08-07 2004-08-02 Sciclone Pharmaceuticals Inc Composicion farmaceutica para el tratamiento de la hepatitis c con timocina, interferon y ribavirin.
US6878364B2 (en) * 2000-12-01 2005-04-12 Cornell Research Foundation, Inc. Animal model for flaviviridae infection
US7138376B2 (en) * 2001-09-28 2006-11-21 Idenix Pharmaceuticals, Inc. Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides
HUP0600449A2 (en) * 2001-10-05 2006-09-28 Intermune Methods of treating liver fibrosis and hepatitis c virus infection
UA81613C2 (ru) * 2001-10-26 2008-01-25 Род Айленд Хоспитл Стимуляция тимозином генетической иммунизации
UA80957C2 (en) * 2001-11-01 2007-11-26 Sciclone Pharmaceuticals Inc Method of administering a thymosin alpha 1 peptide
JP2005522443A (ja) * 2002-02-14 2005-07-28 フアーマセツト・リミテツド 改変フッ素化ヌクレオシド類似体
CN103319554A (zh) 2002-06-28 2013-09-25 埃迪尼克斯医药公司 用于治疗黄病毒感染的修饰的2’和3’-核苷前药
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
US7456155B2 (en) 2002-06-28 2008-11-25 Idenix Pharmaceuticals, Inc. 2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
EP1576138B1 (de) 2002-11-15 2017-02-01 Idenix Pharmaceuticals LLC. 2'-methyl nukleoside in kombination mit interferon und flaviviridae-mutation
KR20050109918A (ko) 2002-12-12 2005-11-22 이데닉스 (케이만) 리미티드 2'-분지형 뉴클레오시드의 제조 방법
GB0301879D0 (en) * 2003-01-27 2003-02-26 Regent Res Llp HCV combination therapy
JP4149296B2 (ja) * 2003-03-26 2008-09-10 株式会社ルネサステクノロジ 半導体記憶装置
ATE467422T1 (de) * 2003-03-28 2010-05-15 Sciclone Pharmaceuticals Inc Behandlung von aspergillus-infektionen mit thymosin alpha 1
CN100342907C (zh) * 2003-03-28 2007-10-17 希克龙制药公司 胸腺素α1在制备用于治疗或预防哺乳动物中曲霉菌感染的药物组合物中的应用
US20100311656A1 (en) * 2003-04-23 2010-12-09 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with alpha thymosin peptides
ES2726998T3 (es) 2003-05-30 2019-10-11 Gilead Pharmasset Llc Análogos de nucleósidos fluorados modificados
RU2006105640A (ru) * 2003-07-25 2007-09-10 Айденикс (Кайман) Лимитед (Ky) Аналоги пуриновых нуклеозидов для лечения flaviviridae, включая гепатит с
WO2005021007A1 (fr) * 2003-08-28 2005-03-10 Obschestvo S Ogranichennoi Otvetstvennostju 'berezovy Mir' Prevention et traitement de l'hepatite virale b
WO2005107742A1 (en) 2004-05-05 2005-11-17 Yale University Novel antiviral helioxanthin analogs
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
NZ554442A (en) 2004-09-14 2011-05-27 Pharmasset Inc Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
JP4516863B2 (ja) * 2005-03-11 2010-08-04 株式会社ケンウッド 音声合成装置、音声合成方法及びプログラム
EP1976382B1 (de) 2005-12-23 2013-04-24 IDENIX Pharmaceuticals, Inc. Verfahren zur herstellung eines synthetischen zwischenprodukts für die herstellung von verzweigten nukleosiden
EP1832295A1 (de) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Verwendung von PTX3 zur Behandlung viraler Erkrankungen
EP2012816B1 (de) * 2006-05-02 2012-06-27 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Verwendung von thymosin 1; allein oder in kombination mit ptx3 oder ganciclovir zur behandlung von cytomegalovirus-infektionen
ES2288118B1 (es) * 2006-05-10 2008-11-01 Bcn Peptides, S.A. Procedimiento para sintetizar timosinas.
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US20110195048A1 (en) * 2008-10-08 2011-08-11 Podack Eckhard R Regulation of lymphocytes and uses therefor
CN102325783A (zh) 2008-12-23 2012-01-18 法莫赛特股份有限公司 嘌呤核苷的合成
CA2748034A1 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Purified 2'-deoxy'2'-fluoro-2'-c-methyl-nucleoside-phosphoramidate prodrugs for the treatment of viral infections
PA8855601A1 (es) 2008-12-23 2010-07-27 Forformidatos de nucleósidos
WO2010129947A2 (en) 2009-05-08 2010-11-11 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (zh) * 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
SG184323A1 (en) 2010-03-31 2012-11-29 Gilead Pharmasett Llc Stereoselective synthesis of phosphorus containing actives
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
CA2818853A1 (en) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
CN103800293B (zh) * 2012-11-09 2015-10-21 长春海悦药业有限公司 一种含有胸腺法新的药物组合物及其制剂
PL3038601T3 (pl) 2013-08-27 2020-08-24 Gilead Pharmasset Llc Formulacja złożona dwóch związków przeciwwirusowych

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1216056B (it) * 1988-03-11 1990-02-22 Sclavo Spa Composizioni farmaceutiche contenenti timosina alfa 1.
US5273963A (en) * 1991-03-29 1993-12-28 The George Washington University Compositions and methods for treating small cell and nonsmall cell lung cancers
TW224053B (de) * 1991-09-13 1994-05-21 Paul B Chretien

Also Published As

Publication number Publication date
JPH06510998A (ja) 1994-12-08
HK1021687A1 (en) 2000-06-23
RU94022480A (ru) 1996-07-20
RU2104010C1 (ru) 1998-02-10
US5849696A (en) 1998-12-15
CA2119006A1 (en) 1993-04-01
NO941310D0 (no) 1994-04-12
FI107879B (fi) 2001-10-31
HU9400758D0 (en) 1994-06-28
DE69219782D1 (de) 1997-06-19
KR100254082B1 (ko) 2000-09-01
AU667327B2 (en) 1996-03-21
NO941310L (no) 1994-04-12
CZ286827B6 (cs) 2000-07-12
US6001799A (en) 1999-12-14
HU221006B1 (hu) 2002-07-29
JP3228512B2 (ja) 2001-11-12
MX9205240A (es) 1993-07-01
US20070218033A1 (en) 2007-09-20
ATE152914T1 (de) 1997-05-15
DK0603305T3 (da) 1997-09-01
WO1993005806A1 (en) 1993-04-01
RO111991B1 (ro) 1997-04-30
FI941133A0 (fi) 1994-03-10
ES2103966T3 (es) 1997-10-01
CZ55194A3 (en) 1994-10-19
GR3024025T3 (en) 1997-10-31
CA2119006C (en) 2005-08-23
SG64897A1 (en) 1999-05-25
ZA926964B (en) 1993-04-26
EP0603305B1 (de) 1997-05-14
FI941133A (fi) 1994-03-10
TW224053B (de) 1994-05-21
HUT75166A (en) 1997-04-28
EP0603305A1 (de) 1994-06-29
AU2644792A (en) 1993-04-27

Similar Documents

Publication Publication Date Title
DE69219782T2 (de) Verwendung eines thymosins bei der behandlung von hepatitis c
FI962613A (fi) Menetelmä inaktivointikäsittelyn virusinaktivointikapasiteetin määrittämiseksi
DE69010893T2 (de) Verfahren zur behandlung von koks sowie löschen desselben.
DE69205966D1 (de) Feinmustergeprägte elastomerfolien und verfahren.
DE69232565D1 (de) Verfahren zur behandlung von lungenerkrankungen mit uridin-triphosphaten
DE69107949T2 (de) MOS-gesteuerter Thyristor und Verfahren zu dessen Herstellung.
DE3889536T2 (de) Behandlung von krebs mit somatostatin und mit analogen davon.
DE69224469T2 (de) Sicherheitsspritze sowie verfahren zum anwenden derselben
DK0380230T3 (da) Immunogene sammensætninger mod gastrin-peptider
DE3771605D1 (de) Verfahren zum verbessern der aufwickelcharakteristiken von thermoplastischen folien und thermoplastische folie, hergestellt nach dem verfahren.
DE69327742T2 (de) Holzbehandlungsverfahren
DE69223141D1 (de) Kontinuierliches verfahren zum strahlungshärten von verbundmaterial im grenzschatten der strahlung
DE68906650D1 (de) Verfahren zur zementierung von plattformbeinen.
SG46620A1 (en) Method and composition foor the treatment of autoimmune hepatitis
DE58902477D1 (de) Verfahren sowie vorrichtung zur reinigung von bodenschichten.
ATE155345T1 (de) Gegengift immunsera
DE59001565D1 (de) Verfahren zur verminderung der resteinspritzmenge von einspritzpumpen.
DE3884652D1 (de) Gate-Ausschaltthyristor und Verfahren zu dessen Herstellung.
DE68907914T2 (de) Verfahren zur behandlung von brandwunden.
ATE107166T1 (de) Verwendung von chlormethiazol zur herstellung eines artzneimittels zur prophylaxe oder therapie der neurodegeneration.
MY129918A (en) Method for treating hypertension.
DE69214139D1 (de) Verfahren zur behandlung von mit feuchtigkeit enthaltenden feinkohlen
DE3886924D1 (de) Halbleiterbauelement mit tiefen Source- und Drainerweiterungen sowie Verfahren zu seiner Herstellung.
DE68905602D1 (de) Verfahren zur behandlung von titanstrukturen.
UA10000A (uk) Спосіб лікування гострої недостатності тканинного дихання

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE

Owner name: THE BOARD OF GOVERNORS OF WAYNE STATE UNIVERSITY,

Owner name: SCICLONE PHARMACEUTICALS, INC., SAN MATEO, CALIF.,